Zydus生命科学公司于2026年2月28日获得美国林业发展局的批准,出售通用的ivermectin和Dapsone平板药。 Zydus Lifesciences gained U.S. FDA approval on Feb. 28, 2026, to sell generic ivermectin and dapsone tablets.

Zydus生命科学公司已经获得美国林业发展局最终批准,销售通用Ivermectin药片(3毫克)和Dapsone药片(25毫克和100毫克),使该公司能够在美国销售这些药物,治疗寄生虫感染,如强效丝虫病和盘尾丝虫病,而Dapsone则用于麻风病和性皮炎。 Zydus Lifesciences has received final U.S. FDA approval to market generic Ivermectin Tablets (3 mg) and Dapsone Tablets (25 mg and 100 mg), enabling the company to sell these drugs in the U.S. Ivermectin treats parasitic infections like strongyloidiasis and onchocerciasis, while Dapsone is used for leprosy and dermatitis herpetiformis. 2026年2月28日宣布的这项批准标志着Zydus在美国非专利药物市场上的重要扩张。 The approvals, announced on February 28, 2026, mark a key expansion for Zydus in the U.S. generic drug market.